Webster Bank N. A. Sells 179 Shares of Gilead Sciences, Inc. (GILD)
Webster Bank N. A. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,652 shares of the biopharmaceutical company’s stock after selling 179 shares during the period. Webster Bank N. A.’s holdings in Gilead Sciences were worth $117,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Kempner Capital Management Inc. lifted its holdings in Gilead Sciences by 3.8% during the 2nd quarter. Kempner Capital Management Inc. now owns 66,890 shares of the biopharmaceutical company’s stock worth $4,734,000 after purchasing an additional 2,428 shares in the last quarter. Union Bankshares Corp raised its holdings in shares of Gilead Sciences by 4.4% in the 2nd quarter. Union Bankshares Corp now owns 6,234 shares of the biopharmaceutical company’s stock valued at $441,000 after acquiring an additional 260 shares in the last quarter. Arvest Bank Trust Division raised its holdings in shares of Gilead Sciences by 1.1% in the 2nd quarter. Arvest Bank Trust Division now owns 238,542 shares of the biopharmaceutical company’s stock valued at $16,884,000 after acquiring an additional 2,665 shares in the last quarter. Pennsylvania Trust Co raised its holdings in shares of Gilead Sciences by 91.9% in the 2nd quarter. Pennsylvania Trust Co now owns 152,251 shares of the biopharmaceutical company’s stock valued at $10,776,000 after acquiring an additional 72,915 shares in the last quarter. Finally, Narwhal Capital Management raised its holdings in shares of Gilead Sciences by 19.1% in the 2nd quarter. Narwhal Capital Management now owns 36,505 shares of the biopharmaceutical company’s stock valued at $2,584,000 after acquiring an additional 5,850 shares in the last quarter. 73.97% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.41% during mid-day trading on Monday, reaching $83.61. The company’s stock had a trading volume of 3,832,730 shares. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The stock has a 50-day moving average price of $77.54 and a 200-day moving average price of $70.38. The company has a market capitalization of $109.19 billion, a price-to-earnings ratio of 9.08 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the business posted $3.08 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.78 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s payout ratio is currently 22.58%.
TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/webster-bank-n-a-sells-179-shares-of-gilead-sciences-inc-gild/1587385.html.
GILD has been the topic of several recent analyst reports. ValuEngine cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a report on Wednesday, June 21st. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Thursday, June 22nd. Eleven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.29.
In other Gilead Sciences news, EVP James R. Meyers sold 60,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the transaction, the executive vice president now owns 62,715 shares in the company, valued at approximately $5,217,260.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold a total of 466,819 shares of company stock valued at $36,740,240 in the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.